NEOLEUKIN THERAPEUTICS INC's ticker is NLTX and the CUSIP is 64049K104. A total of 53 filers reported holding NEOLEUKIN THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $0 | – | 592 | +191.6% | 0.00% | – |
| Q1 2023 | $0 | – | 203 | -1.5% | 0.00% | – |
| Q4 2022 | $0 | – | 206 | -60.8% | 0.00% | – |
| Q3 2022 | $0 | – | 525 | +147.6% | 0.00% | – |
| Q2 2022 | $0 | -100.0% | 212 | -94.2% | 0.00% | – |
| Q1 2022 | $7,000 | -83.7% | 3,663 | -59.0% | 0.00% | – |
| Q4 2021 | $43,000 | +2.4% | 8,935 | +54.5% | 0.00% | – |
| Q3 2021 | $42,000 | -38.2% | 5,782 | -22.0% | 0.00% | – |
| Q2 2021 | $68,000 | -41.9% | 7,411 | -21.8% | 0.00% | – |
| Q1 2021 | $117,000 | 0.0% | 9,483 | +14.6% | 0.00% | – |
| Q4 2020 | $117,000 | +62.5% | 8,274 | +37.0% | 0.00% | – |
| Q3 2020 | $72,000 | -61.5% | 6,039 | -46.5% | 0.00% | – |
| Q2 2020 | $187,000 | -76.1% | 11,287 | -83.6% | 0.00% | – |
| Q1 2020 | $781,000 | +25.8% | 68,674 | +36.4% | 0.00% | – |
| Q4 2019 | $621,000 | +114.9% | 50,359 | -50.2% | 0.00% | – |
| Q3 2019 | $289,000 | – | 101,178 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 2,291,133 | $1,166,187 | 1.01% |
| Privium Fund Management (UK) Ltd | 117,200 | $59,655 | 0.04% |
| Redmile Group, LLC | 1,850,566 | $941,938 | 0.04% |
| Baker Brothers Advisors | 3,821,740 | $1,945,266 | 0.01% |
| Kynam Capital Management, LP | 120,764 | $61,469 | 0.01% |
| Sio Capital Management, LLC | 38,312 | $19,501 | 0.01% |
| SIMON QUICK ADVISORS, LLC | 46,856 | $23,850 | 0.00% |
| Tri Locum Partners LP | 10,248 | $5,000 | 0.00% |
| Endurance Wealth Management, Inc. | 20,000 | $10 | 0.00% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 75,000 | $38,175 | 0.00% |